Bipolar Disorder Trial, Recruiting NCT05958940 Sponsor: Universiteit Leiden Condition: Bipolar Disorder
Back to Bipolar Disorder

Bipolar Disorder Trial, Recruiting

NCT05958940
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 65 years old
  • People who have been diagnosed with unipolar or bipolar depression (whether related to seasons or not), confirmed through a structured psychiatric interview
  • People who are currently experiencing a depressive episode, shown by a score of 6 or higher on a standard self-reported depression questionnaire
  • People who have a sufficient understanding of Dutch or English to complete questionnaires
  • People who have given written informed consent to participate

Who may not be able to join:

  • People who are currently experiencing a manic, hypomanic, or mixed mood episode
  • People who are currently experiencing a psychotic episode
  • People with significant active suicidal thoughts, based on a score of 10 or higher on a standard assessment tool
  • People who started antidepressant treatment — including medication, talking therapy, bright light therapy, or other specific depression treatments — less than 2 months before entering the study
  • People with bipolar disorder who have not been on a mood-stabilising treatment at a recommended dose for at least 1 month
  • People who have used melatonin or agomelatine in the past month
  • People who are currently taking antibiotics
  • People who are currently taking medication that increases sensitivity to light
  • People who have travelled across more than one time zone in the past month, or who plan to do so during the treatment period
  • People who have visited a sunny holiday destination or done winter sports in the past month
  • People with certain pre-existing eye or skin conditions, including retinitis pigmentosa, porphyria, chronic actinic dermatitis, or sun-induced hives
  • People with certain systemic conditions that may affect the eyes, such as rheumatoid arthritis or systemic lupus erythematosus
  • People who have colour blindness, as assessed by a standard colour vision test
  • People who have worked night shifts in the past three months
  • People with blindness (including retinal blindness), severe cataracts, or glaucoma
  • People who experience migraines or epileptic seizures triggered by light
  • People who are pregnant, or parents of a child under 18 months old

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Niki Antypa, PhD, Leiden University

Phone: +31 71 527 6677

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Universiteit Leiden
Registry
ClinicalTrials.gov
Start date
8 February 2024
Est. completion
1 September 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Clinical Improvement

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov